腎福康膠囊對慢性腎功能衰竭模型大鼠的抗氧化作用研究

蔣霞+陸華+程娜+等

蔣 霞1 陸 華1 程 娜2 張洪啟2

1.廣西醫科大學第一附屬醫院藥學部，廣西南寧 530021；2.桂林醫學院藥學院，廣西桂林 541001

[摘要] 目的 探討腎福康膠囊對慢性腎功能衰竭（CRF）模型大鼠的抗氧化作用。 方法 取健康雄性SD大鼠70只，造模前取尾靜脈血，分離血清，進行尿素氮（BUN）含量測定，按BUN水平均衡，隨機分為空白組、模型組、陽性對照組及腎福康低、中、高劑量組，每組10只大鼠。模型組、陽性對照組及腎福康低、中、高劑量組采用灌服腺嘌呤致大鼠CRF模型，同時腎福康組連續給大鼠灌胃腎福康膠囊40 d，分別按低、中、高劑量[0.225、0.45、0.9 g生藥/（kg·d）]進行給藥；陽性對照組給予灌胃尿毒清顆粒[6.7g/（kg·d））]共40 d。造模后12、24 d測定各組大鼠血清BUN、血清肌酐（SCr）含量；造模后第40天測定各組大鼠心、腎臟組織勻漿中超氧化物岐化酶（SOD）及丙二醛（MDA）含量。 結果 模型組大鼠血清BUN、SCr及心、腎組織勻漿中MDA含量明顯高于空白組，SOD含量較空白組顯著性降低（均P < 0.01）。陽性對照組、腎福康中、高劑量組與模型組比較，能顯著降低大鼠血清BUN、SCr及心、腎組織中MDA含量（P < 0.05），明顯增加心、腎組織勻漿液中SOD含量（P < 0.05）。各劑量組間比較，腎福康中、高劑量組在降低大鼠血清BUN、SCr含量，升高腎組織勻漿中SOD含量方面與腎福康低劑量組比較有顯著性優勢（P < 0.05）。 結論 腎福康膠囊具有抗氧化作用，能有效保護CRF大鼠心、腎等重要器官。

[關鍵詞] 腎福康膠囊；慢性腎衰竭；抗氧化

[中圖分類號] R285.5 [文獻標識碼] A [文章編號] 1673-7210（2014）03（b）-0031-04

Anti-oxidation effects of Shenfukang Capsule for rats with chronic renal failure

JIANG Xia1 LU Hua1 CHENG Na2 ZHANG Hongqi2

1.Department of Pharmacy， the First Affiliated Hospital of Guangxi Medical University， Guangxi Zhuang Autonomous Region， Nanning 530021， China； 2.College of Pharmacy， Guilin Medical University， Guangxi Zhuang Autonomous Region， Guilin 541001， China

[Absract] Objective To observe the anti-oxidation effects of Shenfukang Capsule for rats with chronic renal failure （CRF）. Methods 70 SD rats were randomly divided into blank， disease model， positive control and ShenFukang low-dose， middle-dose and high-dose treatment groups according to the levels of blood urea nitrogen （BUN）， each gourp had 10 rats. All groups were fed with adenine to induce CRF model besides blank group. ShenFukang low-dose， middle-dose and high-dose treatment groups were administered according to the dose of 0.225， 0.45， 0.9 g/（kg·d） respectively for 40 days. Positive control group were given NiaoDuqing Granules according to the dose of 6.7 g/（kg·d） for 40 days. The levels of BUN， serum creatinine （SCr） of all groups after molding of 12 days and 24 days were detected， and the contents of superoxide dismutase （SOD）， malondialdehyde （MDA） in heart and kidney after molding of 40 days were detected. Results Compared with blank group， the levels of BUN， SCr， MDA in heart and kidney in model group were obviously higher， while the activities of SOD were obviously lower （all P < 0.01）. The levels of BUN， SCr， MDA in heart and kidney in positive control group， Shenfukang middle-dose and high-dose treatment groups were obviously lower， the activities of SOD were obviously higher compared with model group（all P < 0.05）. The effect of lower BUN， SCr levels and higher SOD activities in Shenfukang middle-dose and high-dose treatment groups were more significant than in Shenfukang low-dose treatment group （P < 0.05）. Conclusion Shenfukang Capsule has the ability of anti-oxidation， can protect important organs such as heart， kidney of rats with CRF.

[Key words] Shenfukang Capsule； Chronic renal failure； Anti-oxidation

腎福康膠囊為廣西醫科大學第一附屬醫院在多年治療腎臟疾病的臨床經驗基礎上研制而成的復方中藥制劑[桂衛藥制字（1999）001250]，由黃芪、大黃等藥組成，對慢性腎功能不全、氮質血癥期、尿毒癥有一定的療效。……